Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition

Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective treatment. The epithelial-mesenchymal transition (EMT) is a critical stage during the development of fibrosis. To assess the effect of sulforaphane (SFN) on the EMT and fibrosis using an in v...

Full description

Bibliographic Details
Main Authors: Sun Young Kyung, Dae Young Kim, Jin Young Yoon, Eun Suk Son, Yu Jin Kim, Jeong Woong Park, Sung Hwan Jeong
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Pharmacology and Toxicology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40360-018-0204-7
id doaj-1f3254d53aa94f9ebb414eefe86a7991
record_format Article
spelling doaj-1f3254d53aa94f9ebb414eefe86a79912020-11-25T01:29:14ZengBMCBMC Pharmacology and Toxicology2050-65112018-04-0119111010.1186/s40360-018-0204-7Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transitionSun Young Kyung0Dae Young Kim1Jin Young Yoon2Eun Suk Son3Yu Jin Kim4Jeong Woong Park5Sung Hwan Jeong6Department of Internal Medicine, Gachon University Gil Medical CenterDepartment of Biological Science, College of Bio-nano Technology, Gachon UniversityDepartment of Internal Medicine, Gachon University Gil Medical CenterDepartment of Internal Medicine, Gachon University Gil Medical CenterDepartment of Internal Medicine, Gachon University Gil Medical CenterDepartment of Internal Medicine, Gachon University Gil Medical CenterDepartment of Internal Medicine, Gachon University Gil Medical CenterAbstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective treatment. The epithelial-mesenchymal transition (EMT) is a critical stage during the development of fibrosis. To assess the effect of sulforaphane (SFN) on the EMT and fibrosis using an in vitro transforming growth factor (TGF)-β1-induced model and an in vivo bleomycin (BLM)-induced model. Methods In vitro studies, cell viability, and cytotoxicity were measured using a Cell Counting Kit-8. The functional TGF-β1-induced EMT and fibrosis were assessed using western blotting and a quantitative real-time polymerase chain reaction. The lungs were analyzed histopathologically in vivo using hematoxylin and eosin and Masson’s trichrome staining. The BLM-induced fibrosis was characterized by western blotting and immunohistochemical analyses for fibronectin, TGF-β1, E-cadherin (E-cad), and α-smooth muscle actin (SMA) in lung tissues. Results SFN reversed mesenchymal-like changes induced by TGF-β1 and restored cells to their epithelial-like morphology. The results confirmed that the expression of the epithelial marker, E-cadherin, increased after SFN treatment, while expression of the mesenchymal markers, N-cadherin, vimentin, and α-SMA decreased in A549 cells after SFN treatment. In addition, SFN inhibited TGF-β1-induced mRNA expression of the EMT-related transcription factors, Slug, Snail, and Twist. The SFN treatment attenuated TGF-β1-induced expression of fibrosis-related proteins, such as fibronection, collagen I, collagen IV, and α-SMA in MRC-5 cells. Furthermore, SFN reduced the TGF-β1-induced phosphorylation of SMAD2/3 protein in A549 cells and MRC-5 cells. BLM induced fibrosis in mouse lungs that was also attenuated by SFN treatment, and SFN treatment decreased BLM-induced fibronectin expression, TGF-β1 expression, and the levels of collagen I in the lungs of mice. Conclusions SFN showed a significant anti-fibrotic effect in TGF-β-treated cell lines and BLM-induced fibrosis in mice. These findings showed that SFN has anti-fibrotic activity that may be considered in the treatment of IPF.http://link.springer.com/article/10.1186/s40360-018-0204-7Idiopathic pulmonary fibrosisBleomycinSulforaphaneEpithelial-mesenchymal transition
collection DOAJ
language English
format Article
sources DOAJ
author Sun Young Kyung
Dae Young Kim
Jin Young Yoon
Eun Suk Son
Yu Jin Kim
Jeong Woong Park
Sung Hwan Jeong
spellingShingle Sun Young Kyung
Dae Young Kim
Jin Young Yoon
Eun Suk Son
Yu Jin Kim
Jeong Woong Park
Sung Hwan Jeong
Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
BMC Pharmacology and Toxicology
Idiopathic pulmonary fibrosis
Bleomycin
Sulforaphane
Epithelial-mesenchymal transition
author_facet Sun Young Kyung
Dae Young Kim
Jin Young Yoon
Eun Suk Son
Yu Jin Kim
Jeong Woong Park
Sung Hwan Jeong
author_sort Sun Young Kyung
title Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
title_short Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
title_full Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
title_fullStr Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
title_full_unstemmed Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
title_sort sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
publisher BMC
series BMC Pharmacology and Toxicology
issn 2050-6511
publishDate 2018-04-01
description Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective treatment. The epithelial-mesenchymal transition (EMT) is a critical stage during the development of fibrosis. To assess the effect of sulforaphane (SFN) on the EMT and fibrosis using an in vitro transforming growth factor (TGF)-β1-induced model and an in vivo bleomycin (BLM)-induced model. Methods In vitro studies, cell viability, and cytotoxicity were measured using a Cell Counting Kit-8. The functional TGF-β1-induced EMT and fibrosis were assessed using western blotting and a quantitative real-time polymerase chain reaction. The lungs were analyzed histopathologically in vivo using hematoxylin and eosin and Masson’s trichrome staining. The BLM-induced fibrosis was characterized by western blotting and immunohistochemical analyses for fibronectin, TGF-β1, E-cadherin (E-cad), and α-smooth muscle actin (SMA) in lung tissues. Results SFN reversed mesenchymal-like changes induced by TGF-β1 and restored cells to their epithelial-like morphology. The results confirmed that the expression of the epithelial marker, E-cadherin, increased after SFN treatment, while expression of the mesenchymal markers, N-cadherin, vimentin, and α-SMA decreased in A549 cells after SFN treatment. In addition, SFN inhibited TGF-β1-induced mRNA expression of the EMT-related transcription factors, Slug, Snail, and Twist. The SFN treatment attenuated TGF-β1-induced expression of fibrosis-related proteins, such as fibronection, collagen I, collagen IV, and α-SMA in MRC-5 cells. Furthermore, SFN reduced the TGF-β1-induced phosphorylation of SMAD2/3 protein in A549 cells and MRC-5 cells. BLM induced fibrosis in mouse lungs that was also attenuated by SFN treatment, and SFN treatment decreased BLM-induced fibronectin expression, TGF-β1 expression, and the levels of collagen I in the lungs of mice. Conclusions SFN showed a significant anti-fibrotic effect in TGF-β-treated cell lines and BLM-induced fibrosis in mice. These findings showed that SFN has anti-fibrotic activity that may be considered in the treatment of IPF.
topic Idiopathic pulmonary fibrosis
Bleomycin
Sulforaphane
Epithelial-mesenchymal transition
url http://link.springer.com/article/10.1186/s40360-018-0204-7
work_keys_str_mv AT sunyoungkyung sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition
AT daeyoungkim sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition
AT jinyoungyoon sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition
AT eunsukson sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition
AT yujinkim sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition
AT jeongwoongpark sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition
AT sunghwanjeong sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition
_version_ 1725097669820416000